Shares of other companies:
April 26, 2024 Top 10 High Dividend Yield Stocks
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
VTRS Stock News and Mentions of Viatris Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Viatris Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Viatris Inc. (VTRS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Viatris stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Viatris Inc. (VTRS)
April 25, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Viatris Sees Relative Strength Rating Climb To 75
On Thursday, Viatris ( VTRS ) earned an upgrade to its Relative Strength ( RS ) Rating, from 69 to 75. X IBD's unique RS Rating measures market leadership by using a 1 ( worst ) to 99 ( best ) score that shows how a stock's price performance over the trailing 52 weeks stacks up against all ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (21:55) / "Zacks Commentary" (by Zacks Equity Research)
Icon PLC ( ICLR ) Beats Q1 Earnings and Revenue Estimates
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.87% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 19, 2024 (10:00) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.
In Article Trend: Somewhat-Bullish
April 18, 2024 (15:12) / "Zacks Commentary" (by Sundeep Ganoria)
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
In Article Trend: Somewhat-Bullish
April 17, 2024 (20:27) / "Benzinga" (by Globe Newswire)
Flagship Communities Real Estate Investment Trust Announces Largest Acquisition in the REIT's History
Not for distribution to U.S. newswire services or dissemination in the United States.
In Article Trend: Somewhat-Bullish
April 16, 2024 (03:01) / "CNBC" (by Ernestine Siu)
These are the top 5 companies to work for in India, according to LinkedIn
LinkedIn has released its eighth annual list of top companies to work for in India. Companies that prioritized its employees' experience and growth dominated.
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:00) / "PR Newswire"
Viatris Appoints Corinne Le Goff as Chief Commercial Officer - PR Newswire
Viatris Appoints Corinne Le Goff as Chief Commercial Officer PR ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (11:47) / "Zacks Commentary" (by Zacks Equity Research)
Strength Seen in Theravance Bio ( TBPH ) : Can Its 7.6% Jump Turn into More Strength?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
In Article Trend: Somewhat-Bullish
April 15, 2024 (10:59) / "Canada Newswire" (by Viatris Inc.)
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
New generic Multiple Sclerosis treatment option, PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world
In Article Trend: Somewhat-Bullish
April 11, 2024 (14:03) / "GlobeNewswire" (by Ocuphire Pharma)
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% ( PS ) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
LYNX-2 Follows SPA Agreement with ...
In Article Trend: Neutral
April 10, 2024 (03:35) / "Money Control"
Lupin gets target hike from Nomura to Rs 1,949 on growth potential in US products
Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.
In Article Trend: Neutral
April 1, 2024 (11:14) / "GlobeNewswire" (by Ocuphire Pharma)
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ ( Phentolamine Ophthalmic Solution 0.75% ) by its Partner Viatris
FARMINGTON HILLS, Mich., April 01, 2024 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. ( Nasdaq: OCUP ) , a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. ...
In Article Trend: Neutral
April 1, 2024 (10:59) / "PR Newswire" (by Viatris Inc.)
Viatris Announces the Launch of RYZUMVl™ ( Phentolamine Ophthalmic Solution ) 0.75% in the United States
PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. ( NASDAQ: VTRS ) , a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ ( phentolamine ophthalmic solution ) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists ( ...
In Article Trend: Neutral
March 29, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Viatris ( VTRS ) Down 3.5% Since Last Earnings Report?
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 29, 2024 (10:30) / "Forbes" (by Bob Ivry)
Why This Value Investor Is Thrilled By Higher Rates
Wall Street scion Christopher Davis hung tough for 14 years as risk-free borrowing pinched value stocks. Now that money costs money again, he's taking advantage of what he calls "a return to normalcy. here's a Mistake Wall in Christopher Davis' office on Fifth Avenue in Manhattan-23 framed stock ...
In Article Trend: Neutral
March 27, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Theravance Bio ( TBPH ) Down 9% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 20, 2024 (15:54) / "Stocknews.com" (by StockNews.com Staff)
VTRS: 3 Pharma Stocks Outperforming the Competition
The pharmaceutical industry's growth prospects appear promising due to advances in the manufacturing of personalized medicines, expanding healthcare needs, a robust drug pipeline, growing investments in research and development, and favorable government policies.
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:30) / "Benzinga" (by Globe Newswire)
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes - Lifecore Biomedical ( NASDAQ:LFCR )
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn., March 20, 2024 ( GLOBE NEWSWIRE ) -- Lifecore Biomedical, Inc.
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:30) / "GlobeNewswire" (by Lifecore Biomedical)
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (06:00) / "GlobeNewswire" (by Idorsia Pharmaceuticals Ltd)
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
Ad hoc announcement pursuant to Art. 53 LR ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:00) / "Benzinga" (by Benzinga Insights)
Looking Into Viatris's Recent Short Interest - Viatris ( NASDAQ:VTRS )
Viatris's VTRS short percent of float has risen 9.15% since its last report. The company recently reported that it has 33.72 million shares sold short, which is 3.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.25 days to cover their ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:53) / "Motley Fool" (by David Jagielski)
Is Viatris a Great Dividend Stock or Just a Value Trap?
Investors can collect a high yield with Viatris, but is it a risky payout to rely on?
In Article Trend: Neutral
March 11, 2024 (13:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 Dirt Cheap Dividend Stocks to Buy and Hold
These companies aren't popular on the market right now, but income investors will like them.
In Article Trend: Somewhat-Bullish
)
March 5, 2024 (10:57) / "Business Standard" (by Vasudha Mukherjee)
Strides Pharma receives USFDA approval for neurology medication Gabapentin | Company News
Strides Pharma receives USFDA approval for neurology medication Gabapentin Business Standard ...
In Article Trend: Neutral
March 5, 2024 (10:25) / "Business Standard" (by Capital Market)
Strides Pharma receives USFDA approval for Gabapentin Tablets | Capital Market News
Strides Pharma receives USFDA approval for Gabapentin Tablets Business Standard ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (08:32) / "Business Standard" (by Capital Market)
Strides Pharma gains on USFDA nod for Gabapentin tablets | Capital Market News
Strides Pharma gains on USFDA nod for Gabapentin tablets Business Standard ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Viatris' ( VTRS ) Generic Declines in Q4, Yupleri Sales Rise
Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:18) / "Zacks Commentary" (by Zacks Equity Research)
Ocuphire ( OCUP ) to Report Q4 Earnings: What's in the Cards?
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
In Article Trend: Neutral
February 28, 2024 (21:10) / "Barrons" (by Barron's Automation)
U.S. Indexes Dropped Wednesday; Viatris Took Biggest Hit
U.S. Indexes Dropped Wednesday. Viatris Took Biggest Hit ...
In Article Trend: Somewhat-Bearish
February 28, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Viatris' ( VTRS ) Q4 Earnings and Revenues Miss Estimates
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
In Article Trend: Neutral
February 28, 2024 (10:20) / "Benzinga" (by Nabaparna Bhattacharya)
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments - Viatris ( NASDAQ:VTRS )
On Wednesday, Viatris Inc. VTRS said it has inked a pact with Idorsia for a significant global research and development collaboration. This partnership involves selatogrel, an innovative self-administered treatment for individuals with a background of acute myocardial infarction ( AMI ) , also ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (06:00) / "Benzinga" (by PRNewswire)
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration - Viatris ( NASDAQ:VTRS )
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand Collaboration With Additional Innovative Assets
In Article Trend: Somewhat-Bullish
February 28, 2024 (06:00) / "GlobeNewswire" (by Idorsia Pharmaceuticals Ltd)
Idorsia and Viatris enter into a significant global research and development collaboration
Ad hoc announcement pursuant to Art. 53 LR ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (16:47) / "Zacks Commentary" (by Zacks Equity Research)
Theravance's ( TBPH ) Q4 Earnings & Revenues Surpass Estimates
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.
In Article Trend: Neutral
February 26, 2024 (21:05) / "PR Newswire" (by Theravance Biopharma)
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ( "Theravance Biopharma" or the "Company" ) ( NASDAQ: TBPH ) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website